MX2011012340A - Quinolinas sustituidas para uso como inhibidores del factor de crecimiento endotelial vascular (vegf). - Google Patents
Quinolinas sustituidas para uso como inhibidores del factor de crecimiento endotelial vascular (vegf).Info
- Publication number
- MX2011012340A MX2011012340A MX2011012340A MX2011012340A MX2011012340A MX 2011012340 A MX2011012340 A MX 2011012340A MX 2011012340 A MX2011012340 A MX 2011012340A MX 2011012340 A MX2011012340 A MX 2011012340A MX 2011012340 A MX2011012340 A MX 2011012340A
- Authority
- MX
- Mexico
- Prior art keywords
- vegf inhibitors
- substituted quinolines
- compound
- psoriasis
- atherosclerosis
- Prior art date
Links
- 229940111121 antirheumatic drug quinolines Drugs 0.000 title 1
- 150000003248 quinolines Chemical class 0.000 title 1
- 239000002525 vasculotropin inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000001344 Macular Edema Diseases 0.000 abstract 1
- 206010025415 Macular oedema Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 201000010230 macular retinal edema Diseases 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto de fórmula (I), así como también a sales del mismo farmacéuticamente aceptables y composiciones farmacéuticas que comprenden una cantidad terapéuticamente efectiva de los compuestos. El compuesto es útil en el tratamiento de cáncer, retinopatía diabética, degeneración macular relacionada con la edad, inflamación apoplejía, miocardio isquémico, aterosclerosis, edema macular y psoriasis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09160829 | 2009-05-20 | ||
| PCT/EP2010/056968 WO2010133669A1 (en) | 2009-05-20 | 2010-05-20 | Substituted quinolines for use as vegf inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011012340A true MX2011012340A (es) | 2011-12-14 |
Family
ID=41152142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011012340A MX2011012340A (es) | 2009-05-20 | 2010-05-20 | Quinolinas sustituidas para uso como inhibidores del factor de crecimiento endotelial vascular (vegf). |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120065199A1 (es) |
| EP (1) | EP2432764A1 (es) |
| JP (1) | JP2012527431A (es) |
| KR (1) | KR20120023807A (es) |
| CN (1) | CN102625798A (es) |
| AU (1) | AU2010251134A1 (es) |
| BR (1) | BRPI1012859A2 (es) |
| CA (1) | CA2762232A1 (es) |
| EA (1) | EA201101658A1 (es) |
| IL (1) | IL216408A0 (es) |
| MX (1) | MX2011012340A (es) |
| SG (1) | SG176167A1 (es) |
| WO (1) | WO2010133669A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9376393B2 (en) * | 2012-01-05 | 2016-06-28 | Clanotech Ab | Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases |
| KR20250053496A (ko) | 2023-10-13 | 2025-04-22 | 재단법인 대구경북첨단의료산업진흥재단 | 안질환 치료제 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0400284D0 (sv) * | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Novel compounds |
| WO2008119771A2 (en) | 2007-03-30 | 2008-10-09 | Clanotech Ab | Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors |
-
2010
- 2010-05-20 SG SG2011085461A patent/SG176167A1/en unknown
- 2010-05-20 CN CN201080033815XA patent/CN102625798A/zh active Pending
- 2010-05-20 JP JP2012511290A patent/JP2012527431A/ja not_active Withdrawn
- 2010-05-20 WO PCT/EP2010/056968 patent/WO2010133669A1/en not_active Ceased
- 2010-05-20 AU AU2010251134A patent/AU2010251134A1/en not_active Abandoned
- 2010-05-20 CA CA2762232A patent/CA2762232A1/en not_active Abandoned
- 2010-05-20 EP EP10723066A patent/EP2432764A1/en not_active Withdrawn
- 2010-05-20 BR BRPI1012859A patent/BRPI1012859A2/pt not_active IP Right Cessation
- 2010-05-20 MX MX2011012340A patent/MX2011012340A/es not_active Application Discontinuation
- 2010-05-20 EA EA201101658A patent/EA201101658A1/ru unknown
- 2010-05-20 KR KR1020117030328A patent/KR20120023807A/ko not_active Withdrawn
- 2010-05-20 US US13/321,602 patent/US20120065199A1/en not_active Abandoned
-
2011
- 2011-11-17 IL IL216408A patent/IL216408A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120065199A1 (en) | 2012-03-15 |
| CA2762232A1 (en) | 2010-11-25 |
| JP2012527431A (ja) | 2012-11-08 |
| CN102625798A (zh) | 2012-08-01 |
| WO2010133669A1 (en) | 2010-11-25 |
| IL216408A0 (en) | 2012-02-29 |
| KR20120023807A (ko) | 2012-03-13 |
| EP2432764A1 (en) | 2012-03-28 |
| SG176167A1 (en) | 2011-12-29 |
| BRPI1012859A2 (pt) | 2016-04-05 |
| AU2010251134A1 (en) | 2011-12-08 |
| EA201101658A1 (ru) | 2012-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500072A1 (en) | Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| IN2015DN00185A (es) | ||
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| MX2016000675A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos. | |
| SG194463A1 (en) | Glycoside derivatives and their uses for the treatment of diabetes | |
| MX2016006667A (es) | Derivados de pirrolo-pirrolona y su uso como inhibidores. | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| PH12015501752B1 (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| MX364400B (es) | Compuestos de tetraciclina. | |
| EA201391524A1 (ru) | Производные гликозида и их применение | |
| MX2010005039A (es) | Derivados de quinolina y su uso como inhibidores de tirosina quinasa. | |
| MX2015010434A (es) | Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo. | |
| MX2011012340A (es) | Quinolinas sustituidas para uso como inhibidores del factor de crecimiento endotelial vascular (vegf). | |
| TN2015000058A1 (en) | Salts of benzothiazolone compound as beta-2-adrenoceptor agonist | |
| CY1116412T1 (el) | Παραγωγα κινολινης, φαρμακευτικες συνθεσεις περιεχουσες αυτα, και χρηση αυτων | |
| TN2013000052A1 (en) | Oxadiazole inhibitors of leukotriene production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |